查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1733329

全球麻醉剂市场规模（按应用、给药途径、给药方式、区域范围和预测）

Global Anesthesia Drugs Market Size By Application, By Administrative Route, By Mode Of Delivery, By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格
简介目录

麻醉剂市场规模及预测

麻醉剂市场规模预计在 2024 年达到 67.7 亿美元，到 2032 年将达到 87.7 亿美元，2026 年至 2032 年的复合年增长率为 3.64%。

麻醉剂，俗称麻醉剂，是用来引起暂时失去感觉和意识的药物，使医疗程序更容易进行，且不会产生疼痛或痛苦。

麻醉剂是一种能够产生可控的无意识状态或局部麻木状态的药物，使患者能够接受手术或医疗程序而不会感到疼痛或不适。麻醉剂主要分为两大类：全身麻醉剂和局部麻醉剂。

这些药物的主要目的是阻断手术介入期间的感觉，尤其是疼痛。麻醉剂使患者感到舒适并且不知道正在进行的手术，这对于小手术和大手术都至关重要。

麻醉剂透过与中枢神经系统 (CNS) 相互作用并抑制疼痛信号从周围神经向大脑传输而发挥作用。全身麻醉剂会改变神经传导物质活性，局部麻醉剂会阻断神经纤维中的钠通道。

麻醉剂市场动态

影响麻醉剂市场的关键市场动态是：

关键市场驱动因素

外科手术数量增加：根据美国麻醉师协会的数据，全球每年进行超过 3.1 亿次外科手术，仅在美国就进行约 4,000 万至 5,000 万次外科手术。对外科手术的高需求需要有效的麻醉解决方案，从而推动市场成长。

慢性病盛行率上升：癌症、心血管疾病和骨关节炎等慢性病盛行率上升是麻醉剂需求的主要驱动因素。根据世界卫生组织 (WHO) 的数据，心血管疾病是全球第一大死因，并推动了对需要全身麻醉的外科手术的需求。这一趋势凸显了麻醉在复杂医疗状况管理中的重要性。

技术进步：麻醉剂配方和输送方法的不断创新正在提高患者的安全性和有效性。最近的趋势包括开发超短效麻醉剂和改善患者预后的先进监测系统。在这些技术进步的推动下，美国全身麻醉剂市场预计在 2024 年至 2030 年期间的复合年增长率为 2.8%。

政府资金和支持：增加私人和政府机构对製药製造研究和开发的资金也很重要。例如，美国政府旨在改善医疗保健基础设施的倡议正在间接推动对麻醉剂的需求。

主要市场挑战

麻醉剂高成本：麻醉剂价格过高会限制人们获得所需药物的机会，尤其是在低收入地区。根据报告，预计在预测期内，高昂的手术成本和品牌药物成本将抑制市场成长。这种经济障碍常常阻碍人们寻求必要的医疗干预，特别是在医疗预算有限的低度开发国家。

缺乏医疗保健基础设施：世界卫生组织 (WHO) 强调，医疗保健基础设施不足直接影响手术的可用性和可近性，进而限制对麻醉剂的需求。这种差距在新兴国家尤其明显，因为这些国家的麻醉师与认证麻醉护理师的比例较低。

意外的术中知晓：儘管处于全身麻醉状态，患者在手术过程中仍可能意识到周围环境。研究表明，每 1,000 名患者中大约有 1 到 2 名可能会出现这种状况，这会导致类似于创伤后压力症候群 (PTSD) 的长期心理问题。这种风险可能会使患者不愿意接受需要全身麻醉的手术。

监管挑战：麻醉剂市场受到美国食品药物管理局(FDA) 和欧洲药品管理局 (EMA) 等卫生当局的严格监管和核准程序。这些监管障碍可能会减缓新药和创新产品的市场推广，并限制医疗保健提供者和患者的选择。

主要市场趋势

外科手术数量的增加：全球外科手术数量正在增加，这是麻醉剂需求的主要驱动力。根据美国整形整形外科协会的数据，2022 年共进行了约 2,620 万例外科手术。这一趋势表明，随着医疗保健提供者寻求满足人口老化和日益增长的医疗需求，对有效麻醉解决方案的需求日益增长。

技术进步：得益于超短效麻醉剂和监测技术改进等进步，全身麻醉剂市场预计在 2026 年至 2032 年期间的复合年增长率为 3.5%。这些创新有望缩短恢復时间并减少术后併发症。

门诊手术中心 (ASC) 的成长：门诊手术中心 (ASC) 的门诊手术明显增多，这需要高效的麻醉管理。预计美国全身麻醉剂市场在 2024 年至 2030 年期间的复合年增长率将达到 2.8%，部分原因是在 ASC 中进行的手术数量不断增加，因为这对患者来说更具成本效益且更加方便。

更重视病人安全和照护品质：在外科手术环境中，人们更加重视改善病人的治疗效果和安全性，这推动了先进麻醉技术和药物的采用。政府为提高医疗品质所做的努力也促进了这一趋势，例如医疗保险等项目涵盖了各种需要麻醉的外科手术。

麻醉剂市场区域分析

亚太地区

亚太地区正在对医疗保健基础设施进行大量投资，包括新医院和外科中心的建设。据报道，在政府改善医疗服务取得途径和品质的措施的推动下，亚洲的医疗保健支出预计到 2025 年将达到 1 兆美元。随着更多外科手术成为可能，这种扩张直接增加了对麻醉剂的需求。

亚太地区处于医疗创新的前沿，尤其是在麻醉技术方面。根据各种行业分析，预计该地区从 2024 年到 2033 年将以 5.09% 的速度成长，成为预测期内成长最快的麻醉剂市场。

亚太地区心血管疾病和癌症等慢性疾病的发生率正在上升，需要进行更多的外科手术。 《2022年中国心血管疾病报告》显示，心血管疾病是中国首要的死亡原因，推动了必要手术的需求。这一趋势凸显了在应对这些健康挑战时对有效麻醉剂的迫切需求。

亚太地区处于医疗创新的前沿，尤其是在麻醉技术方面。根据各种行业分析，预计该地区从 2024 年到 2033 年将以 5.09% 的速度成长，成为预测期内成长最快的麻醉剂市场。

北美洲

预计北美将成为最大的地区，到 2023 年将占全球麻醉剂市场的约 45.2%。这项优势源自于成熟的医疗基础设施，支持各种需要麻醉的外科手术。

据美国医院协会称，该地区的手术量很大，医院每年进行大量的外科手术。 2022 年，美国将进行约 2,620 万例外科手术，这表明对这些手术所需的麻醉剂的需求强劲。

心血管疾病和癌症等慢性疾病的发生率不断上升，推动了对外科手术介入的需求。美国癌症协会估计，2024年将有近201万例新的癌症病例，这将导致更多的手术，从而增加对麻醉的需求。

药物配方和给药方法的不断创新正在提高患者的安全性和疗效。由于技术进步缩短了恢復时间并减少了麻醉相关併发症，预计 2024 年至 2033 年间全身麻醉剂市场将以 3% 的复合年增长率成长。

麻醉剂市场区隔分析

麻醉剂市场（按应用）

  • 一般外科
  • 整形外科
  • 眼科
  • 牙科
  • 疼痛治疗

根据应用，它分为普通外科、整形外科、眼科、牙科和疼痛管理。根据记录，2023 年普通外科手术领域占了 46.8% 的显着收益占有率。这种主导地位归因于麻醉剂在各种外科手术中的广泛使用，使其成为市场上最大的应用领域。

麻醉剂市场（依给药途径）

  • 吸入
  • 静脉注射
  • 局部麻醉
  • 局部入侵

根据给药途径，市场分为吸入、静脉（IV）、局部和局部浸润。静脉注射药物领域在 2023 年获得了 56.4% 的显着市场收益占有率。这项优点归功于静脉注射的效率和可靠性，可以在手术过程中提供精确的剂量并快速开始麻醉。

麻醉剂市场（依分娩方式划分）

  • 预填充式注射器和管瓶
  • 安瓿
  • 定量吸入器（MDI）

根据交付方式，市场分为预填充式注射器和管瓶、安瓿瓶和定量吸入器 (MDI)。预填充式注射器和管瓶因其便利性和效率而占据麻醉剂市场的很大份额。这些在紧急情况下特别有用，因为它们可以实现准确的剂量并减少准备时间。

主要参与企业

  • 麻醉剂市场研究报告提供了针对全球市场的宝贵见解。雅培实验室、艾伯维公司、阿斯特捷利康公司、罗氏公司、辉瑞公司、Aspen Pharmacare Holdings Limited、百特国际公司、勃林格殷格翰国际有限公司、Claris Lifesciences Limited、丸石製药株式会社、迈兰製药有限公司、迈兰製药有限公司、Pacira Pharmaceuticals, Inc.

我们的市场分析还设有专门针对这些主要企业的部分，我们的分析师在其中提供所有主要企业的财务报表见解以及产品基准评效和 SWOT 分析。竞争格局部分还包括上述全球参与企业的关键发展策略、市场占有率和市场排名分析。

  • 麻醉剂市场的最新趋势
  • 2024 年 2 月，Hikma Pharmaceuticals 推出了柠檬酸Fentanyl注射 USP，用于维持、诱导、术前用药、麻醉和术后恢復期间的短期镇痛。该产品满足了各种手术环境中有效疼痛管理的迫切需求。
  • 2023年6月，阿斯特捷利康与Aspen Global Incorporated（AGI）建立策略伙伴关係，以扩大其麻醉剂组合在美国以外的商业化。该协议涵盖几种成熟的麻醉剂产品，增加了它们在全球市场的供应，并利用了 AGI 广泛的商业网络。

目录

第一章全球麻醉剂市场简介

  • 市场概览
  • 研究范围
  • 先决条件

第二章执行摘要

第三章：已验证的市场研究调查方法

  • 资料探勘
  • 验证
  • 第一手资料
  • 资料来源列表

第四章 全球麻醉剂市场展望

  • 概述
  • 市场动态
    • 驱动程式
    • 限制因素
    • 机会
  • 波特五力模型
  • 价值链分析

第五章全球麻醉剂市场（按应用）

  • 概述
  • 一般外科
  • 整形外科
  • 眼科
  • 牙科
  • 疼痛治疗

第六章全球麻醉剂市场（依给药途径）

  • 概述
  • 吸入
  • 静脉注射
  • 局部麻醉
  • 局部入侵

第七章全球麻醉剂市场以交付方式

  • 概述
  • 预填充式注射器和管瓶
  • 安瓿
  • 定量吸入器（MDI）

第八章全球麻醉剂市场（按地区）

  • 概述
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 其他欧洲国家
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 其他亚太地区
  • 其他的
    • 拉丁美洲
    • 中东和非洲

第九章全球麻醉剂市场的竞争格局

  • 概述
  • 各公司市场排名
  • 重点发展策略

第十章 公司简介

  • Abbott Laboratories
  • AbbVie, Inc.
  • AstraZeneca PLC
  • F. Hoffmann-La Roche Ltd.
  • Pfizer, Inc.
  • Aspen Pharmacare Holdings Limited
  • Baxter International, Inc.
  • Boehringer Ingelheim International GmbH
  • Claris Lifesciences Limited
  • Maruishi Pharmaceutical Co. Ltd.
  • Mylan NV
  • Pacira Pharmaceuticals, Inc

第十一章 附录

  • 相关调查
简介目录
Product Code: 63890

Anesthesia Drugs Market Size And Forecast

Anesthesia Drugs Market size was valued at USD 6.77 Billion in 2024 and is projected to reach USD 8.77 Billion by 2032, growing at a CAGR of 3.64% from 2026 to 2032.

Anesthesia drugs, commonly referred to as anesthetics, are medications used to induce a temporary loss of sensation or awareness, facilitating medical procedures without causing pain or distress.

Anesthesia drugs are agents that produce a state of controlled unconsciousness or localized numbness, allowing patients to undergo surgical or medical procedures without experiencing pain or They can be classified into two primary categories: general anesthetics and local anesthetics.

The primary purpose of these drugs is to block sensory perception, particularly pain, during surgical interventions. They ensure that patients remain comfortable and unaware of the procedure being performed, which is crucial for both minor and major.

Anesthesia drugs work by interacting with the central nervous system (CNS) to inhibit the transmission of pain signals from peripheral nerves to the brain. General anesthetics may alter neurotransmitter activity, while local anesthetics block sodium channels in nerve fibers.

Anesthesia Drugs Market Dynamics

The key market dynamics that are shaping the Anesthesia Drugs Market include:

Key Market Drivers:

Increasing Surgical Procedures: The rising volume of surgical procedures globally is a primary driver of the anesthesia drugs According to the American Society of Anesthesiologists, over 310 million surgeries are performed each year worldwide, with approximately 40 to 50 million occurring in the United States alone. This high demand for surgical interventions necessitates effective anesthesia solutions, thereby propelling market growth.

Rising Prevalence of Chronic Diseases: The growing incidence of chronic diseases such as cancer, cardiovascular diseases, and osteoarthritis significantly drives the demand for anesthesia drugs. The World Health Organization reported that cardiovascular diseases are the leading cause of global mortality, increasing the need for surgical procedures that require general anesthesia. This trend underscores the importance of anesthesia in managing complex medical conditions.

Technological Advancements: Continuous innovations in anesthesia drug formulations and delivery methods enhance patient safety and efficacy. Recent advancements include the development of ultra-short-acting anesthetics and advanced monitoring systems that improve patient The U.S. general Anesthesia Drugs Market is projected to grow at a CAGR of 2.8% from 2024 to 2030, driven by these technological improvements.

Government Funding and Support: Increased funding from both private and government organizations for research and development in pharmaceutical manufacturing is another significant This funding supports the development of new and safer anesthetic agents, contributing to market expansion. For instance, U.S. government initiatives aimed at improving healthcare infrastructure indirectly boost the demand for anesthesia drugs.

Key Market Challenges:

High Cost of Anesthesia Drugs: The exorbitant prices of anesthesia drugs can limit access to necessary medications, particularly in low-income regions. According to a report, the high cost of procedures and branded drugs is expected to suppress market growth during the forecast This financial barrier often deters individuals from seeking essential medical interventions, particularly in underdeveloped countries where healthcare budgets are constrained.

Lack of Healthcare Infrastructure: In many low-income and remote areas, there is a significant lack of healthcare facilities equipped to provide anesthesia The World Health Organization has highlighted that inadequate healthcare infrastructure directly affects the availability and accessibility of surgical services, which in turn limits the demand for anesthesia drugs. This gap is particularly pronounced in developing countries where the ratio of anesthesiologists and certified anesthesia nurses is low.

Unintentional Intraoperative Awareness: A critical challenge in the anesthesia market is the phenomenon of unintentional intraoperative awareness, where patients may become aware of their surroundings during surgery despite being under general anesthesia. Studies suggest that approximately 1 to 2 out of every 1,000 patients may experience this condition, which can lead to long-term psychological issues similar to post-traumatic stress disorder (PTSD). This risk can deter patients from undergoing surgeries requiring general anesthesia.

Regulatory Challenges: The Anesthesia Drugs Market is subject to stringent regulations and approval processes imposed by health authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). These regulatory hurdles can slow down the introduction of new drugs and innovations in the market, limiting options for healthcare providers and patients.

Key Market Trends:

Increasing Surgical Procedures: The number of surgical procedures is on the rise globally, significantly driving the demand for anesthesia drugs. According to the American Society of Aesthetic Plastic Surgeons, there were approximately 26.2 million surgical procedures performed in the U.S. in 2022. This trend indicates a growing need for effective anesthesia solutions as healthcare providers aim to meet the demands of an aging population and increasing healthcare needs.

Technological Advancements: Continuous innovations in anesthesia drug formulations and delivery methods are enhancing patient safety and The market for general anesthesia drugs is projected to grow at a CAGR of 3.5% from 2026 to 2032, driven by advancements such as ultra-short-acting anesthetics and improved monitoring technologies. These innovations are expected to improve recovery times and reduce postoperative complications.

Growth in Ambulatory Surgery Centers (ASCs): There is a notable shift towards outpatient surgeries performed in Ambulatory Surgery Centers (ASCs), which require efficient anesthesia management. The U.S. general Anesthesia Drugs Market is expected to grow at a CAGR of 2.8% from 2024 to 2030, partly due to the increasing number of procedures being performed in ASCs, which are often more cost-effective and convenient for patients.

Rising Focus on Patient Safety and Quality of Care: There is an increasing emphasis on improving patient outcomes and safety in surgical settings, which drives the adoption of advanced anesthesia techniques and drugs. Government initiatives aimed at enhancing healthcare quality also contribute to this trend, as seen in programs like Medicare that cover a wide range of surgical procedures requiring anesthesia.

Anesthesia Drugs Market Regional Analysis

Asia Pacific:

The Asia Pacific region is witnessing substantial investments in healthcare infrastructure, including the construction of new hospitals and surgical centers. According to a report, healthcare spending in Asia is projected to reach USD 1 Trillion by 2025, driven by government initiatives aimed at improving healthcare access and quality. This expansion directly increases the demand for anesthesia drugs as more surgical procedures become available.

Asia Pacific is at the forefront of medical innovation, particularly in anesthesia technology. Advances in drug formulations and monitoring devices enhance patient safety and anesthetic The region is expected to host the fastest-growing Anesthesia Drugs Market during the projected period, with a growth rate forecasted at 5.09% from 2024 to 2033, as reported by various industry analyses.

The prevalence of chronic diseases such as cardiovascular conditions and cancer is increasing in Asia Pacific, necessitating more surgical interventions. The China Cardiovascular Disease Report 2022 indicates that cardiovascular diseases are the leading cause of death in China, driving demand for surgeries that require This trend underscores the critical need for effective anesthesia drugs in managing these health challenges.

Asia Pacific is at the forefront of medical innovation, particularly in anesthesia technology. Advances in drug formulations and monitoring devices enhance patient safety and anesthetic The region is expected to host the fastest-growing Anesthesia Drugs Market during the projected period, with a growth rate forecasted at 5.09% from 2024 to 2033, as reported by various industry analyses.

North America:

North America captured approximately 45.2% of the global Anesthesia Drugs Market in 2023, making it the largest regional This dominance is attributed to a well- established healthcare infrastructure that supports extensive surgical procedures requiring anesthesia.

The region experiences a high volume of surgeries, with the American Hospital Association reporting that hospitals perform a substantial number of surgical procedures annually. In 2022, around 26.2 million surgical procedures were conducted in the S., indicating a robust demand for anesthesia drugs to facilitate these operations.

The increasing prevalence of chronic diseases such as cardiovascular diseases and cancer drives the need for surgical interventions. The American Cancer Society estimated nearly 2.01 million new cancer cases in the U.S. in 2024, which will necessitate more surgeries and subsequently increase the demand for anesthesia

Continuous innovations in drug formulations and delivery methods enhance patient safety and efficacy. The general Anesthesia Drugs Market is projected to grow at a CAGR of 3% from 2024 to 2033, driven by advancements that improve recovery times and reduce complications associated with anesthesia.

Anesthesia Drugs Market Segmentation Analysis

Anesthesia Drugs Market, By Application

  • General Surgery
  • Orthopedic Surgery
  • Ophthalmology
  • Dentistry
  • Pain Treatment

Based on Application, the market is segmented into energy General Surgery, Orthopedic Surgery, Ophthalmology, Dentistry, and Pain Treatment. The general surgery segment captured a substantial revenue share of 46.8% in 2023. This dominance is attributed to the extensive use of anesthesia drugs during a wide range of surgical procedures, making it the largest application area in the market.

Anesthesia Drugs Market, By Administrative Route

  • Inhalational
  • Intravenous (IV)
  • Topical
  • Local Infiltration

Based on Administrative Route, the market is segmented into Inhalational, Intravenous (IV), Topical, and Local Infiltration. The intravenous drug segment captured a remarkable market revenue share of 56.4% in 2023. This dominance is attributed to the efficiency and reliability of IV administration, which allows for precise dose delivery and rapid onset of anesthesia during surgical procedures.

Anesthesia Drugs Market, By Mode of Delivery

  • Pre-filled Syringes and Vials
  • Ampoules
  • Metered-dose inhalers (MDIs)

Based on Mode of Delivery, the market is divided into Pre-filled Syringes and Vials, Ampoules, and Metered-Dose Inhalers (MDIs). Pre-filled syringes and vials account for a significant share of the Anesthesia Drugs Market due to their convenience and efficiency. They are favored for their ability to provide accurate dosing and reduce preparation time, making them particularly useful in emergency situations.

Key Players

  • The "Anesthesia Drugs Market" study report will provide valuable insight with an emphasis on the global market. The major players in the Abbott Laboratories, AbbVie, Inc., AstraZeneca PLC, F. Hoffmann-La Roche Ltd., Pfizer, Inc., Aspen Pharmacare Holdings Limited, Baxter International, Inc., Boehringer Ingelheim International GmbH, Claris Lifesciences Limited, Maruishi Pharmaceutical Co. Ltd., Mylan NV, Pacira Pharmaceuticals, Inc.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above- mentioned players globally.

  • Anesthesia Drugs Market Recent Developments
  • In February 2024, Hikma Pharmaceuticals launched Fentanyl Citrate Injection, USP, designed for short-duration analgesia during maintenance, induction, premedication, anesthesia, and immediate postoperative recovery. This product addresses a critical need for effective pain management in various surgical settings.
  • In June 2023, AstraZeneca entered into a strategic partnership with Aspen Global Incorporated (AGI) to expand the commercialization of its anesthesia medicines portfolio outside the U.S. This agreement covers several established anesthetic products, enhancing their availability in global markets and leveraging AGI's extensive commercial network.

TABLE OF CONTENTS

1. INTRODUCTION OF GLOBAL ANESTHESIA DRUGS MARKET

  • 1.1. Overview of the market
  • 1.2. Scope of the report
  • 1.3. Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL ANESTHESIA DRUGS MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5. GLOBAL ANESTHESIA DRUGS MARKET, BY APPLICATION

  • 5.1 Overview
  • 5.2 General Surgery
  • 5.3 Orthopedic Surgery
  • 5.4 Ophthalmology
  • 5.5 Dentistry
  • 5.6 Pain Treatment

6. GLOBAL ANESTHESIA DRUGS MARKET, BY ADMINISTRATIVE ROUTE

  • 6.1 Overview
  • 6.2 Inhalational
  • 6.3 Intravenous (IV)
  • 6.4 Topical
  • 6.5 Local Infiltration

7. GLOBAL ANESTHESIA DRUGS MARKET, BY MODE OF DELIVERY

  • 7.1 Overview
  • 7.2 Pre-filled Syringes and Vials
  • 7.3 Ampoules
  • 7.4 Metered-dose inhalers (MDIs)

8 GLOBAL ANESTHESIA DRUGS MARKET, BY GEOGRAPHY

  • 8.1 Overview
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 U.K.
    • 8.3.3 France
    • 8.3.4 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Rest of Asia Pacific
  • 8.5 Rest of the World
    • 8.5.1 Latin America
    • 8.5.2 Middle East and Africa

9. GLOBAL ANESTHESIA DRUGS MARKET COMPETITIVE LANDSCAPE

  • 9.1 Overview
  • 9.2 Company market ranking
  • 9.3 Key development strategies

10. Company profiles

  • 10.1 Abbott Laboratories
    • 10.1.1 Overview
    • 10.1.2 Financial performance
    • 10.1.3 Product Outlook
    • 10.1.4 Key Developments
  • 10.2 AbbVie, Inc.
    • 10.2.1 Overview
    • 10.2.2 Financial performance
    • 10.2.3 Product Outlook
    • 10.2.4 Key Developments
  • 10.3 AstraZeneca PLC
    • 10.3.1 Overview
    • 10.3.2 Financial performance
    • 10.3.3 Product Outlook
    • 10.3.4 Key Developments
  • 10.4 F. Hoffmann-La Roche Ltd.
    • 10.4.1 Overview
    • 10.4.2 Financial performance
    • 10.4.3 Product Outlook
    • 10.4.4 Key Developments
  • 10.5 Pfizer, Inc.
    • 10.5.1 Overview
    • 10.5.2 Financial performance
    • 10.5.3 Product Outlook
    • 10.5.4 Key Developments
  • 10.6 Aspen Pharmacare Holdings Limited
    • 10.6.1 Overview
    • 10.6.2 Financial performance
    • 10.6.3 Product Outlook
    • 10.6.4 Key Developments
  • 10.7 Baxter International, Inc.
    • 10.7.1 Overview
    • 10.7.2 Financial performance
    • 10.7.3 Product Outlook
    • 10.7.4 Key Developments
  • 10.8 Boehringer Ingelheim International GmbH
    • 10.8.1 Overview
    • 10.8.2 Financial performance
    • 10.8.3 Product Outlook
    • 10.8.4 Key Developments
  • 10.9 Claris Lifesciences Limited
    • 10.9.1 Overview
    • 10.9.2 Financial performance
    • 10.9.3 Product Outlook
    • 10.9.4 Key Developments
  • 10.10 Maruishi Pharmaceutical Co. Ltd.
    • 10.10.1 Overview
    • 10.10.2 Financial performance
    • 10.10.3 Product Outlook
    • 10.10.4 Key Developments
  • 10.11 Mylan NV
    • 10.11.1 Overview
    • 10.11.2 Financial performance
    • 10.11.3 Product Outlook
    • 10.11.4 Key Developments
  • 10.12 Pacira Pharmaceuticals, Inc
    • 10.12.1 Overview
    • 10.12.2 Financial performance
    • 10.12.3 Product Outlook
    • 10.12.4 Key Developments

11. Appendix

  • 11.1 Related Research